Germacrone Reduces Cisplatin-Induced Toxicity of Renal Proximal Tubular Cells via Inhibition of Organic Cation Transporter

Author:

Soodvilai Sirima1,Meetam Paranee2,Siangjong Lawan2,Chokchaisiri Ratchanaporn3,Suksamrarn Apichart4,Soodvilai Sunhapas5

Affiliation:

1. Department of Pharmaceutical Technology, College of Pharmacy, Rangsit University

2. Department of Biopharmacy, Faculty of Pharmacy, Silpakorn University

3. Department of Chemistry, School of Science, University of Phayao

4. Department of Chemistry and Center of Excellence for Innovation in Chemistry, Faculty of Science, Ramkhamhaeng University

5. Research Center of Transporter Protein for Medical Innovation and Department of Physiology, Faculty of Science, Mahidol University

Publisher

Pharmaceutical Society of Japan

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Reference30 articles.

1. 1) Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer, 7, 573–584 (2007).

2. 2) Frezza M, Hindo S, Chen D, Davenport A, Schmitt S, Tomco D, Dou QP. Novel metals and metal complexes as platforms for cancer therapy. Curr. Pharm. Des., 16, 1813–1825 (2010).

3. 3) Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol., 21, 3194–3200 (2003).

4. 4) Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N. Engl. J. Med., 357, 1705–1715 (2007).

5. 5) Williams S, Blessing JA, Liao SY, Ball H, Hanjani P. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group. J. Clin. Oncol., 12, 701–706 (1994).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3